Patents by Inventor Kristen BALTGALVIS

Kristen BALTGALVIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20220298213
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO: 1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 22, 2022
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF
    Publication number: 20210380703
    Abstract: The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.
    Type: Application
    Filed: August 4, 2021
    Publication date: December 9, 2021
    Inventors: Todd M. KINSELLA, Ramesh BHATT, Kristen BALTGALVIS
  • Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
    Patent number: 11111305
    Abstract: This invention describes the design of bispecific antibodies that function as conditionally effective therapeutics by binding to a functionally silent epitope on one component of a targeted signaling complex and simultaneously binding to a second protein, whose expression or accessibility is cell- or disease environment-specific, and whose antibody-driven proximity to the signaling complex leads to an alteration of signal transduction.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: September 7, 2021
    Assignee: TORCH THERAPEUTICS
    Inventors: Todd M. Kinsella, Donald G. Payan, Ramesh Bhatt, Kristen Baltgalvis
  • ACVR2A-specific antibody and method of treatment of muscle atrophy
    Patent number: 11104737
    Abstract: The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: August 31, 2021
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Todd M. Kinsella, Ramesh Bhatt, Kristen Baltgalvis
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20210002337
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • In vivo engineered cereblon protein
    Patent number: 10781239
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 22, 2020
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: David Weinstein, Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, Ekaterina Vinogradova, Brian Nordin, Kristen Baltgalvis, Todd Kinsella
  • ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF
    Publication number: 20190382496
    Abstract: The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.
    Type: Application
    Filed: March 27, 2018
    Publication date: December 19, 2019
    Inventors: Todd M. KINSELLA, Ramesh BHATT, Kristen BALTGALVIS
  • CONDITIONALLY EFFECTIVE BISPECIFIC THERAPEUTICS
    Publication number: 20190345252
    Abstract: This invention describes the design of bispecific antibodies that function as conditionally effective therapeutics by binding to a functionally silent epitope on one component of a targeted signaling complex and simultaneously binding to a second protein, whose expression or accessibility is cell- or disease environment-specific, and whose antibody-driven proximity to the signaling complex leads to an alteration of signal transduction.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 14, 2019
    Inventors: Todd M. KINSELLA, Donald G. PAYAN, Ramesh BHATT, Kristen BALTGALVIS